Eikon Therapeutics, Inc., a late-stage clinical biopharmaceutical company dedicated to integrating advanced engineering with ...

In a small phase II trial, radiation-free treatment with pembrolizumab (Keytruda) and platinum-based chemotherapy alone ...

The U.S. Food and Drug Administration recently approved Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) for ...

Hamlin was given the treatment as part of a clinical trial after receiving a diagnosis of melanoma last year. She recently ...

Confirmation of 30mg efti as optimal biological dose relevant for Immutep’s oncology pipeline and potential future Biological License ...

"ESMO 2025: Anticipated Phase II data debut for Eikon’s NSCLC candidate" was originally created and published by Clinical ...

Gilead and Arcus Bioscience’s monoclonal antibody (mAb), domvanalimab, has produced positive results in a Phase II ...

Welcome to The Pharma Letter’s real-time coverage of the 2025 European Society of Medical Oncology (ESMO) Congress, taking place October 17 to 21 in Berlin, Germany. This feed will deliver concise ...

MIT and Harvard scientists recently created engineered CAR-NK cells that hide from the immune system and more effectively ...

Immutep ( ($IMMP) ) just unveiled an announcement. Immutep Limited announced on October 13, 2025, the successful completion of the FDA’s Project ...

Moderna faces significant uncertainty ahead of Q3 earnings, with heavy reliance on COVID vaccine revenues and limited ...

If approved in RCC, fruquintinib will be available for three indications, including endometrial and colorectal cancer.